^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    7d
    SCAN-LITE: Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening (clinicaltrials.gov)
    P=N/A, N=101, Active, not recruiting, Massachusetts Eye and Ear Infirmary | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jan 2026 | Trial primary completion date: Jul 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    7d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    7d
    Immunodeficiency, HIV Viremia, and Incident Anal Cancer Among People With HIV in South Africa. (PubMed, Open Forum Infect Dis)
    Lower CD4 counts and, to a lesser extent, higher HIV RNA viral loads were associated with an increased anal cancer risk. Maintaining high CD4 counts may contribute to anal cancer prevention among PWH in South Africa.
    Journal
    |
    CD4 (CD4 Molecule)
    10d
    Prognostic analysis of local excision in 153 cases of locally advanced low rectal cancer following neoadjuvant therapy (PubMed, Zhonghua Wei Chang Wai Ke Za Zhi)
    At 1 year after surgery, 10 cases (10.5%, 10/95) had severe anal dysfunction, and the median LARS score of the entire group was 5.0 (range: 0-41.0) points. For patients with locally advanced low rectal cancer who achieve cCR or near-cCR after neoadjuvant therapy, local excision results in favorable oncological prognosis and anal function preservation effects; however, the incidence of complications is relatively high.
    Retrospective data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    10d
    Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients. (PubMed, NPJ Precis Oncol)
    Four clinical examples illustrated LB-guided therapies. This largest-to-date aSCC cohort reinforces molecular profiling-especially LB-as a key tool for guiding personalized therapy.
    Journal • Liquid biopsy • Tumor mutational burden • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • KMT2D (Lysine Methyltransferase 2D) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    TP53 mutation • EGFR mutation • TMB-H • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • FGFR2 mutation
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    14d
    Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report. (PubMed, Cancer Chemother Pharmacol)
    This case report supports the clinical utility of pre-emptive DPYD genotyping to guide initial 5-FU dosing in intermediate metabolizers, and it suggests that all patients still require close monitoring and some (particularly carriers of c.2846 A > T) may require an initial dose reduction greater than the recommended 50% to prevent severe toxicity.
    Journal
    |
    DPYD (Dihydropyrimidine Dehydrogenase)
    |
    5-fluorouracil • capecitabine • mitomycin
    15d
    Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV. (PubMed, Int J Cancer)
    In PWH with CD4 ≥ 500/mm3 for at least 2 years and with recent viral load ≤50 copies/mL, risks of virus-related cancers (KS, NHL, HL, liver, and anal cancer) remained significantly higher relative to the general population, albeit to a lesser extent than in PWH overall, while risks of lung and cervical cancers were similar. Over 20 years, the incidence of all virus-related cancers continued to fall but in the most recent period, the risks still remained higher than in the general population.
    Journal
    |
    CD4 (CD4 Molecule)
    17d
    SCOPE: Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis (clinicaltrials.gov)
    P=N/A, N=296, Recruiting, Universitair Ziekenhuis Brussel | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Active, not recruiting, TScan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    21d
    Injury and inflammation promote cancer progression at the anorectal junction. (PubMed, Cell Rep)
    We showed that this tumoral development was under the influence of interleukin (IL)-17, a cytokine highly secreted by a γδ T lymphocyte subset, allowing the recruitment of neutrophils at the TZ, which was crucial for tumor progression. Hence, this study reveals the importance of wound and its associated IL-17/neutrophil inflammatory axis in cancer progression.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • IL17A (Interleukin 17A)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    23d
    SOLO: Self-sampling to Optimize Anal Lesion Outcomes (clinicaltrials.gov)
    P=N/A, N=572, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open